Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab

Fig. 1

C6M biomarker concentration over time. A LS means by treatment and visit for the first 16 weeks in the full population. Treatment and visit as fixed effects and interaction between treatment and visit, baseline C6M as covariate, and patient ID as random effect. B LS means by escape status, treatment, and visit. Escape status, treatment, and visit as interacting fixed effects and patient ID as random effect. Tables indicated the number of ENR out of the total number of patients at each timepoint and dose, and the number of patients who provided samples at all timepoints. Data are shown as least square means ± 95% CI and significance levels as * for p < 0.05, ** for p < 0.01, *** for p < 0.001 for comparison to placebo + MTX (A) and placebo + MTX responder group (B). # designates comparison between ENR and responders within group

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us